Based upon preclinical studies, E-selectin antagonist, GMI-1271, has the potential to disrupt known pathways of tumor resistance, thereby increasing the efficacy of chemotherapy. It may also address both metastasis (cancer’s spread) and thromboembolic complications (those occurring when a blood vessel is blocked by a blood clot dislodged from its site of origin). In addition, in preclinical models, GMI-1271 reduces neutropenia and mucositis caused by chemotherapy. We have selected acute myeloid leukemia (AML) and multiple myeloma (MM) as the initial target disease indications for the compound, and clinical trials are being conducted in both of these diseases. We have conducted preclinical studies to explore the compound’s use in other cancers as well as in other diseases in which E-selectin plays a role. GMI-1271 has not been approved for use by any worldwide health authority.
Read the results of our Phase 1/2 clinical trial in AML as presented at the 2017 ASH meeting.
Visit our Scientific Publications page to review data for GMI-1271 that have been presented at medical meetings.
» Read more about our Pipeline & Other Programs.